164 related articles for article (PubMed ID: 31938346)
1. Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells.
Shi Y; Bieerkehazhi S; Ma H
Int J Clin Exp Pathol; 2018; 11(5):2347-2355. PubMed ID: 31938346
[TBL] [Abstract][Full Text] [Related]
2. Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.
Shi Y; Yu Y; Wang Z; Wang H; Bieerkehazhi S; Zhao Y; Suzuk L; Zhang H
Oncotarget; 2016 Nov; 7(45):73697-73710. PubMed ID: 27655642
[TBL] [Abstract][Full Text] [Related]
3. A Second-Generation Proteasome Inhibitor and Doxorubicin Modulates IL-6, pSTAT-3 and NF-kB Activity in MDA-MB-231 Breast Cancer Cells.
Vyas D; Lopez-Hisijos N; Shah P; Deshpande KS; Basson MD; Vyas A; Chaturvedi LS
J Nanosci Nanotechnol; 2017 Jan; 17(1):175-85. PubMed ID: 29617099
[TBL] [Abstract][Full Text] [Related]
4. Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis.
Wang H; Yu Y; Jiang Z; Cao WM; Wang Z; Dou J; Zhao Y; Cui Y; Zhang H
Sci Rep; 2016 May; 6():26456. PubMed ID: 27217076
[TBL] [Abstract][Full Text] [Related]
5. Apatinib-induced NF-κB inactivation sensitizes triple-negative breast cancer cells to doxorubicin.
Tang D; Ma J; Chu Z; Wang X; Zhao W; Zhang Q
Am J Transl Res; 2020; 12(7):3741-3753. PubMed ID: 32774731
[TBL] [Abstract][Full Text] [Related]
6. P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
Deshmukh RR; Kim S; Elghoul Y; Dou QP
J Cell Biochem; 2017 May; 118(5):1239-1248. PubMed ID: 27813130
[TBL] [Abstract][Full Text] [Related]
7. TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells.
Wang Z; Zhang H; Shi M; Yu Y; Wang H; Cao WM; Zhao Y; Zhang H
Sci Rep; 2016 Sep; 6():32737. PubMed ID: 27599572
[TBL] [Abstract][Full Text] [Related]
8. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
9. Interference KRT17 reverses doxorubicin resistance in triple-negative breast cancer cells by Wnt/β-catenin signaling pathway.
Wu L; Ding W; Wang X; Li X; Yang J
Genes Genomics; 2023 Oct; 45(10):1329-1338. PubMed ID: 37634232
[TBL] [Abstract][Full Text] [Related]
10. Elevated estrogen receptor β expression in triple negative breast cancer cells is associated with sensitivity to doxorubicin by inhibiting the PI3K/AKT/mTOR signaling pathway.
Lei S; Fan P; Wang M; Zhang C; Jiang Y; Huang S; Fang M; He Z; Wu A
Exp Ther Med; 2020 Aug; 20(2):1630-1636. PubMed ID: 32742395
[TBL] [Abstract][Full Text] [Related]
11. Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma.
Vandewynckel YP; Coucke C; Laukens D; Devisscher L; Paridaens A; Bogaerts E; Vandierendonck A; Raevens S; Verhelst X; Van Steenkiste C; Libbrecht L; Geerts A; Van Vlierberghe H
Oncotarget; 2016 Jun; 7(23):34988-5000. PubMed ID: 27167000
[TBL] [Abstract][Full Text] [Related]
12. Alcohol promotes migration and invasion of triple-negative breast cancer cells through activation of p38 MAPK and JNK.
Zhao M; Howard EW; Parris AB; Guo Z; Zhao Q; Yang X
Mol Carcinog; 2017 Mar; 56(3):849-862. PubMed ID: 27533114
[TBL] [Abstract][Full Text] [Related]
13. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
[TBL] [Abstract][Full Text] [Related]
14. Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer.
Chen D; Ma Y; Li P; Liu M; Fang Y; Zhang J; Zhang B; Hui Y; Yin Y
Molecules; 2019 Jun; 24(12):. PubMed ID: 31242627
[TBL] [Abstract][Full Text] [Related]
15. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer.
Dai W; Yang F; Ma L; Fan Y; He B; He Q; Wang X; Zhang H; Zhang Q
Biomaterials; 2014 Jul; 35(20):5347-5358. PubMed ID: 24726747
[TBL] [Abstract][Full Text] [Related]
16. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
[TBL] [Abstract][Full Text] [Related]
17. In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach.
Fleisher B; Lezeau J; Werkman C; Jacobs B; Ait-Oudhia S
Breast Cancer (Dove Med Press); 2021; 13():87-105. PubMed ID: 33628047
[TBL] [Abstract][Full Text] [Related]
18. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
[TBL] [Abstract][Full Text] [Related]
19. The new-generation proteasome inhibitor oprozomib increases the sensitivity of cervical cancer cells to cisplatin-induced apoptosis.
Li QZ; Sun LP; Shi HY; Chen Y; Shen H
J Biol Regul Homeost Agents; 2021; 35(2):559-569. PubMed ID: 33973461
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin.
Inao T; Iida Y; Moritani T; Okimoto T; Tanino R; Kotani H; Harada M
Oncotarget; 2018 May; 9(39):25545-25556. PubMed ID: 29876007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
